SEC Info - Panbela Therapeutics, Inc. - ‘10-K’ for 12/31/23

SEC Info℠

Home

My Interests

Help

Please Sign In

Panbela Therapeutics, Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.CAL’

On: Tuesday, 3/26/24, at 4:15pm ET · For: 12/31/23 · Accession #: 1437749-24-9418 · File #: 1-39468

Previous ‘10-K’: ‘10-K’ on 3/16/23 for 12/31/22 · Latest ‘10-K’: This Filing · 28 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/26/24  Panbela Therapeutics, Inc.        10-K       12/31/23   70:6.5M                                   RDG Filings/FA

Annual Report — Form 10-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.52M 
 2: EX-21.1     Subsidiaries List                                   HTML     21K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     20K 
 4: EX-24.1     Power of Attorney                                   HTML     30K 
 9: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     39K 
                Awarded Compensation                                             
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
15: R1          Document And Entity Information                     HTML     90K 
16: R2          Consolidated Balance Sheets                         HTML    115K 
17: R3          Consolidated Balance Sheets (Parentheticals)        HTML     41K 
18: R4          Consolidated Statements of Operations and           HTML     78K 
                Comprehensive Loss                                               
19: R5          Consolidated Statements of Stockholders' Equity     HTML    107K 
                (Deficit)                                                        
20: R6          Consolidated Statements of Cash Flows               HTML    112K 
21: R7          Consolidated Statements of Cash Flows               HTML     26K 
                (Parentheticals)                                                 
22: R8          Insider Trading Arrangements                        HTML     29K 
23: R9          Note 1 - Business                                   HTML     27K 
24: R10         Note 2 - Risks and Uncertainties                    HTML     26K 
25: R11         Note 3 - Liquidity and Management Plans             HTML     29K 
26: R12         Note 4 - Summary of Significant Accounting          HTML     52K 
                Policies                                                         
27: R13         Note 5 - Accrued Expenses                           HTML     32K 
28: R14         Note 6 - Asset Acquisition                          HTML     41K 
29: R15         Note 7 - Notes Payable                              HTML     28K 
30: R16         Note 8 - Commitments and Contingencies              HTML     28K 
31: R17         Note 9 - Stockholders' Equity                       HTML     47K 
32: R18         Note 10 - Stock-based Compensation                  HTML    105K 
33: R19         Note 11 - Income Taxes                              HTML     68K 
34: R20         Note 12 - Subsequent Events                         HTML     24K 
35: R21         Significant Accounting Policies (Policies)          HTML     88K 
36: R22         Note 4 - Summary of Significant Accounting          HTML     28K 
                Policies (Tables)                                                
37: R23         Note 5 - Accrued Expenses (Tables)                  HTML     31K 
38: R24         Note 6 - Asset Acquisition (Tables)                 HTML     37K 
39: R25         Note 9 - Stockholders' Equity (Tables)              HTML     26K 
40: R26         Note 10 - Stock-based Compensation (Tables)         HTML    105K 
41: R27         Note 11 - Income Taxes (Tables)                     HTML     68K 
42: R28         Note 1 - Business (Details Textual)                 HTML     22K 
43: R29         Note 2 - Risks and Uncertainties (Details Textual)  HTML     49K 
44: R30         Note 3 - Liquidity and Management Plans (Details    HTML     34K 
                Textual)                                                         
45: R31         Note 4 - Summary of Significant Accounting          HTML     28K 
                Policies (Details Textual)                                       
46: R32         Note 4 - Summary of Significant Accounting          HTML     25K 
                Policies - Anti-dilutive Securities (Details)                    
47: R33         Note 5 - Accrued Expenses - Accrued Expenses        HTML     31K 
                (Details)                                                        
48: R34         Note 6 - Asset Acquisition (Details Textual)        HTML     23K 
49: R35         Note 6 - Asset Acquisition - Schedule of Purchase   HTML     57K 
                Consideration and Allocation (Details)                           
50: R36         Note 7 - Notes Payable (Details Textual)            HTML     43K 
51: R37         Note 8 - Commitments and Contingencies (Details     HTML     43K 
                Textual)                                                         
52: R38         Note 9 - Stockholders' Equity (Details Textual)     HTML    114K 
53: R39         Note 9 - Stockholders' Equity - Common Stock        HTML     26K 
                Reserved for Future Issuance (Details)                           
54: R40         Note 10 - Stock-based Compensation (Details         HTML     66K 
                Textual)                                                         
55: R41         Note 9 - Stock-based Compensation - Summary of      HTML     42K 
                Option Activity (Details)                                        
56: R42         Note 11 - Stock-based Compensation - Stock-based    HTML     24K 
                Compensation Expense (Details)                                   
57: R43         Note 11 - Stock-based Compensation - Nonvested      HTML     36K 
                Share Activity (Details)                                         
58: R44         Note 9 - Stock-based Compensation - Options         HTML     54K 
                Outstanding (Details)                                            
59: R45         Note 10 - (Details)                                 HTML     33K 
60: R46         Note 11 - Income Taxes (Details Textual)            HTML     21K 
61: R47         Note 11 - Income Taxes - Deferred Tax Assets and    HTML     36K 
                Liabilities (Details)                                            
62: R48         Note 11 - Income Taxes - Income Tax Reconciliation  HTML     37K 
                (Details)                                                        
63: R49         Note 11 - Income Taxes - Components of Tax Expense  HTML     30K 
                (Details)                                                        
64: R50         Note 11 - Income Taxes - Net Operating Losses and   HTML     31K 
                Tax Credit Carryforwards (Details)                               
65: R51         Note 12 - Subsequent Events (Details Textual)       HTML     49K 
67: XML         IDEA XML File -- Filing Summary                      XML    120K 
70: XML         XBRL Instance -- pbla20231231_10k_htm                XML   1.09M 
66: EXCEL       IDEA Workbook of Financial Report Info              XLSX    115K 
14: EX-101.CAL  XBRL Calculations -- pbla-20231231_cal               XML    117K 
11: EX-101.DEF  XBRL Definitions -- pbla-20231231_def                XML   1.06M 
12: EX-101.LAB  XBRL Labels -- pbla-20231231_lab                     XML    871K 
13: EX-101.PRE  XBRL Presentations -- pbla-20231231_pre              XML   1.09M 
10: EX-101.SCH  XBRL Schema -- pbla-20231231                         XSD    164K 
68: JSON        XBRL Instance as JSON Data -- MetaLinks              366±   579K 
69: ZIP         XBRL Zipped Folder -- 0001437749-24-009418-xbrl      Zip    519K

‘EX-101.CAL’ — XBRL Calculations — pbla-20231231_cal

This Exhibit is an XBRL File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://panbela.com/20231231/role/statement-consolidated-balance-sheets-" xlink:href="pbla-20231231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>

<link:calculationLink xlink:role="http://panbela.com/20231231/role/statement-consolidated-balance-sheets-" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="us-gaap_OtherLongTermDebtCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IncomeTaxesReceivable" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLongTermDebtCurrent" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://panbela.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="pbla-20231231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>

<link:calculationLink xlink:role="http://panbela.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>

<link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>

<link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://panbela.com/20231231/role/statement-consolidated-statements-of-cash-flows" xlink:href="pbla-20231231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>

<link:calculationLink xlink:role="http://panbela.com/20231231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">

<link:loc xlink:href="pbla-20231231.xsd#pbla_PaymentsForFractionalShares" xlink:label="pbla_PaymentsForFractionalShares" xlink:type="locator"/>

<link:loc xlink:href="pbla-20231231.xsd#pbla_ProceedsFromIssuanceOfCommonStockNet" xlink:label="pbla_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>

<link:loc xlink:href="pbla-20231231.xsd#pbla_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="pbla_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="locator"/>

<link:loc xlink:href="pbla-20231231.xsd#pbla_ResearchAndDevelopmentAssetWriteoff" xlink:label="pbla_ResearchAndDevelopmentAssetWriteoff" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pbla_ResearchAndDevelopmentAssetWriteoff" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>

<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc"/>

<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>

<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>

<link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>

<link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pbla_ProceedsFromIssuanceOfCommonStockNet" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pbla_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>

<link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pbla_PaymentsForFractionalShares" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://panbela.com/20231231/role/statement-note-5-accrued-expenses-accrued-expenses-details" xlink:href="pbla-20231231.xsd#statement-note-5-accrued-expenses-accrued-expenses-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://panbela.com/20231231/role/statement-note-5-accrued-expenses-accrued-expenses-details" xlink:type="extended">

<link:loc xlink:href="pbla-20231231.xsd#pbla_AccruedSupplementalUnemploymentBenefitsSeveranceBenefitsAndPayrollTaxesCurrent" xlink:label="pbla_AccruedSupplementalUnemploymentBenefitsSeveranceBenefitsAndPayrollTaxesCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbla-20231231.xsd#pbla_ClinicalTrialRelatedLiabilitiesCurrent" xlink:label="pbla_ClinicalTrialRelatedLiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pbla_ClinicalTrialRelatedLiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pbla_AccruedSupplementalUnemploymentBenefitsSeveranceBenefitsAndPayrollTaxesCurrent" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://panbela.com/20231231/role/statement-note-6-asset-acquisition-schedule-of-purchase-consideration-and-allocation-details" xlink:href="pbla-20231231.xsd#statement-note-6-asset-acquisition-schedule-of-purchase-consideration-and-allocation-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://panbela.com/20231231/role/statement-note-6-asset-acquisition-schedule-of-purchase-consideration-and-allocation-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://panbela.com/20231231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="pbla-20231231.xsd#statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://panbela.com/20231231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">

<link:loc xlink:href="pbla-20231231.xsd#pbla_DeferredTaxAssetsCapitalizedResearchAndDevelopmentAmortization" xlink:label="pbla_DeferredTaxAssetsCapitalizedResearchAndDevelopmentAmortization" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pbla_DeferredTaxAssetsCapitalizedResearchAndDevelopmentAmortization" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>

<link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://panbela.com/20231231/role/statement-note-11-income-taxes-income-tax-reconciliation-details" xlink:href="pbla-20231231.xsd#statement-note-11-income-taxes-income-tax-reconciliation-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://panbela.com/20231231/role/statement-note-11-income-taxes-income-tax-reconciliation-details" xlink:type="extended">

<link:loc xlink:href="pbla-20231231.xsd#pbla_EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent" xlink:label="pbla_EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent" xlink:type="locator"/>

<link:loc xlink:href="pbla-20231231.xsd#pbla_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pbla_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pbla_EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pbla_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>

<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://panbela.com/20231231/role/statement-note-11-income-taxes-components-of-tax-expense-details" xlink:href="pbla-20231231.xsd#statement-note-11-income-taxes-components-of-tax-expense-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://panbela.com/20231231/role/statement-note-11-income-taxes-components-of-tax-expense-details" xlink:type="extended">

<link:loc xlink:href="pbla-20231231.xsd#pbla_IncomeTaxExpenseBenefitNoncurrent" xlink:label="pbla_IncomeTaxExpenseBenefitNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="pbla_IncomeTaxExpenseBenefitNoncurrent" xlink:type="arc"/>

</link:calculationLink>

</link:linkbase>

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/18/24  Panbela Therapeutics, Inc.        S-1                   63:6.5M                                   RDG Filings/FA
 3/29/24  Panbela Therapeutics, Inc.        S-1                    4:518K                                   RDG Filings/FA
 3/29/24  Panbela Therapeutics, Inc.        POS AM                 2:385K                                   RDG Filings/FA

25 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/29/24  Panbela Therapeutics, Inc.        8-K:1,3,7,9 1/28/24   16:835K                                   RDG Filings/FA
 1/19/24  Panbela Therapeutics, Inc.        8-K:3,5,8,9 1/18/24   12:183K                                   RDG Filings/FA
 1/04/24  Panbela Therapeutics, Inc.        S-1         1/03/24   11:3.5M                                   RDG Filings/FA
12/21/23  Panbela Therapeutics, Inc.        8-K:1,3,7,912/21/23   14:448K                                   RDG Filings/FA
 6/21/23  Panbela Therapeutics, Inc.        8-K:1,3,7,8 6/16/23   19:1.4M                                   RDG Filings/FA
 4/18/23  Panbela Therapeutics, Inc.        8-K:1,3,5,9 4/14/23   14:379K                                   RDG Filings/FA
 1/31/23  Panbela Therapeutics, Inc.        8-K:1,3,7,8 1/26/23   17:996K                                   RDG Filings/FA
 1/17/23  Panbela Therapeutics, Inc.        8-K:3,5,7,8 1/11/23   13:233K                                   RDG Filings/FA
10/04/22  Panbela Therapeutics, Inc.        8-K:1,3,7,8 9/29/22   17:1.3M                                   RDG Filings/FA
 8/15/22  Panbela Therapeutics, Inc.        10-Q        6/30/22   51:3.9M                                   RDG Filings/FA
 6/16/22  Panbela Therapeutics, Inc.        8-K12B:1,2, 6/15/22   22:1.1M                                   RDG Filings/FA
 3/24/22  Panbela Therapeutics, Inc.        10-K       12/31/21   64:5.4M                                   RDG Filings/FA
 3/25/21  Panbela Therapeutics, Inc.        10-K       12/31/20   63:4.4M                                   RDG Filings/FA
 9/01/20  Panbela Therapeutics, Inc.        8-K:1,7,8,9 8/28/20    5:501K                                   RDG Filings/FA
 7/16/20  Panbela Therapeutics, Inc.        8-K:5,7,9   7/15/20    3:169K                                   RDG Filings/FA
 6/11/20  Panbela Therapeutics, Inc.        8-K:1,3,9   6/05/20    3:248K                                   RDG Filings/FA
 5/26/20  Panbela Therapeutics, Inc.        8-K:5,9     5/19/20    2:154K                                   RDG Filings/FA
 3/24/20  Panbela Therapeutics, Inc.        10-K       12/31/19   65:4.7M                                   RDG Filings/FA
10/09/19  Panbela Therapeutics, Inc.        8-K:1,9    10/03/19    2:44K                                    RDG Filings/FA
 8/29/19  Panbela Therapeutics, Inc.        8-K:1,3,9   8/23/19    3:205K                                   RDG Filings/FA
12/28/18  Panbela Therapeutics, Inc.        8-K:1,9    12/21/18    4:298K                                   RDG Filings/FA
 5/14/18  Panbela Therapeutics, Inc.        10-Q        3/31/18   47:2.8M                                   RDG Filings/FA
 3/30/17  Panbela Therapeutics, Inc.        10-K       12/31/16   65:5.2M                                   RDG Filings/FA
 8/11/16  Panbela Therapeutics, Inc.        10-Q        6/30/16   51:2.5M                                   RDG Filings/FA
 9/11/15  Panbela Therapeutics, Inc.        8-K:1,2,3,4 9/04/15   17:2.9M                                   Discount Edgar/FA

↑Top

Filing Submission 0001437749-24-009418 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Panbela Therapeutics, Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.CAL’

On: Tuesday, 3/26/24, at 4:15pm ET · For: 12/31/23 · Accession #: 1437749-24-9418 · File #: 1-39468

Annual Report — Form 10-K — SEA’34Filing Table of Contents

‘EX-101.CAL’ — XBRL Calculations — pbla-20231231_cal

This Exhibit is an XBRL File.

3 Subsequent Filings that Reference this Filing

25 Previous Filings that this Filing References

Annual Report — Form 10-K — SEA’34

Filing Table of Contents